

1: Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med.* 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. PubMed PMID: 28002688.

2: Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med.* 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. PubMed PMID: 28002679.

3: Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med.* 2012 Sep 20;367(12):1098-107. Erratum in: *N Engl J Med.* 2012 Dec 13;367(24):2362. PubMed PMID: 22992073.

4: Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. PubMed PMID: 20089960.

5: Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006 Mar 2;354(9):899-910. PubMed PMID: 16510744.

6: Giovannoni G. The neurodegenerative prodrome in multiple sclerosis. *Lancet Neurol.* 2017 Jun;16(6):413-414. doi: 10.1016/S1474-4422(17)30127-8. PubMed PMID: 28504102.

7: Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2016 Mar;15(3):259-69. doi: 10.1016/S1474-4422(16)00004-1. Epub 2016 Jan 26. PubMed PMID: 26822749.

8: Giovannoni G, Baker D, Schmierer K. Simvastatin in patients with progressive multiple sclerosis. *Lancet.* 2014 Sep 13;384(9947):952. doi: 10.1016/S0140-6736(14)61621-4. PubMed PMID: 25220965.

9: Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. *Lancet Neurol.* 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19. PubMed PMID: 24656609.

10: Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4. PubMed PMID: 23562009.

11: Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with

relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet*. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. PubMed PMID: 23122652.

12: Giovannoni G. The REFLEX study: a missed opportunity? *Lancet Neurol*. 2012 Jan;11(1):22-4. doi: 10.1016/S1474-4422(11)70282-4. Epub 2011 Dec 4. PubMed PMID: 22146410.

13: Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. *Lancet Neurol*. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0. PubMed PMID: 21397565.

14: Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. *Lancet Neurol*. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. PubMed PMID: 20610349.

15: Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. *Lancet Neurol*. 2010 Jul;9(7):727-39. doi: 10.1016/S1474-4422(10)70094-6. Review. PubMed PMID: 20610348.

16: Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. *Lancet Neurol*. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: *Lancet Neurol*. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea]. PubMed PMID: 20298967.

17: Ramagopalan SV, Giovannoni G. Can we predict multiple sclerosis? *Lancet Neurol*. 2009 Dec;8(12):1077-9. doi: 10.1016/S1474-4422(09)70273-X. Epub 2009 Oct 29. PubMed PMID: 19879193.

18: Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. *Lancet Neurol*. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7. PubMed PMID: 19201654.

19: Giovannoni G, Cutter GR, Lunemann J, Martin R, Münz C, Sriram S, Steiner I, Hammerschlag MR, Gaydos CA. Infectious causes of multiple sclerosis. *Lancet Neurol*. 2006 Oct;5(10):887-94. Review. PubMed PMID: 16987736.

20: Giovannoni G, Deisenhammer F. Neutralising antibodies against interferon beta in multiple sclerosis. *Lancet*. 2004 Jan 10;363(9403):166-7; author reply 168-9. PubMed PMID: 14726177.